Leukemia Clinical Trials in Wuhan
8 recruitingWuhan, China
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 1
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
AMLMDSLeukemia+2 more
Cullgen (Shanghai),Inc45 enrolled3 locationsNCT07347171
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Chronic Myeloid Leukemia
Peking University People's Hospital30 enrolled15 locationsNCT06390306
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466